Molecular Oncology Research Center-Barretos Cancer Hospital, Brazil.
Duke Cancer Institute, Duke University, Durham, NC, United States of America.
PLoS One. 2020 Apr 22;15(4):e0232105. doi: 10.1371/journal.pone.0232105. eCollection 2020.
Cervical cancer is a significant public health problem, especially in low- and middle-income countries, where women have little access to cervical cancer screening; consequently 80% of cervical cancer related mortality occurs in these regions. The development of screening methods that need less infrastructure thus represents an urgent medical need. The study aims to compare the detection rates of high-risk human papillomavirus 16 and 18 E6 oncoprotein in urine, vaginal self-collected, and cervical scrapes of women using the OncoE6™ Cervical Test and compare the HPV16 and/or HPV18 E6 detection rates with the HPV DNA testing. Paired urine, vaginal self-collected and cervical specimens were collected from 124 women who participated in cervical cancer screening or treatment in this proof-of-concept study and underwent to HPV16/18-E6 testing and high-risk HPV DNA testing prior to treatment of cervical neoplasia or cancer. Concordance between urinary, vaginal and cervical HPV16/18-E6 and HPV-DNA testing was evaluated for patients classified as negative group (<CIN2) and histological positive group (CIN2, CIN3 and invasive carcinoma). Overall, HPV16/18-E6 oncoprotein was detected in 30.6% of cervical samples, 20.3% of self-collected vaginal samples and 21% of urine samples. Regarding the clinical sensitivity, the HPV16/18-E6 oncoprotein was not detected in CIN2 cases, and was detected at low rates in CIN3 cases. The clinical sensitivity of the HPV16/18-E6 oncoprotein for detecting invasive cervical cancer was 70% for cervical scrapes, 55% for self-collected vaginal samples and 52% for urine samples. This study reports the urinary detection of E6 oncoprotein in vivo for the first time and our results suggest that this detection is only for invasive/microinvasive lesions. Then, further protocol development and standardization to achieve a clinical sensitivity for CIN2/3 detection close to what can be achieved for invasive lesions using the physician collected cervical is needed.
宫颈癌是一个重大的公共卫生问题,特别是在中低收入国家,那里的女性很少有机会接受宫颈癌筛查;因此,80%的宫颈癌相关死亡发生在这些地区。因此,开发需要较少基础设施的筛查方法代表了一种迫切的医疗需求。本研究旨在比较使用 OncoE6™ 宫颈测试在尿液、阴道自我采集和宫颈刮片中检测高危型人乳头瘤病毒 16 和 18 E6 癌蛋白的检出率,并比较 HPV16 和/或 HPV18 E6 检测率与 HPV DNA 检测。在这项概念验证研究中,从参加宫颈癌筛查或治疗的 124 名女性中采集配对的尿液、阴道自我采集和宫颈标本,在治疗宫颈上皮内瘤变或癌症之前,这些女性接受了 HPV16/18-E6 检测和高危型 HPV DNA 检测。对于分类为阴性组(<CIN2)和组织学阳性组(CIN2、CIN3 和浸润性癌)的患者,评估了尿、阴道和宫颈 HPV16/18-E6 和 HPV-DNA 检测的一致性。总体而言,在 30.6%的宫颈样本、20.3%的自我采集阴道样本和 21%的尿液样本中检测到 HPV16/18-E6 癌蛋白。关于临床敏感性,HPV16/18-E6 癌蛋白在 CIN2 病例中未被检测到,在 CIN3 病例中以低速率被检测到。HPV16/18-E6 癌蛋白对检测浸润性宫颈癌的临床敏感性为宫颈刮片 70%、自我采集阴道样本 55%和尿液样本 52%。本研究首次报道了体内 E6 癌蛋白的尿液检测,我们的结果表明,这种检测仅适用于侵袭性/微侵袭性病变。然后,需要进一步制定方案并标准化,以实现使用医生采集的宫颈接近检测侵袭性病变的临床敏感性来检测 CIN2/3。